A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

The purpose of this study is to investigate the efficacy and safety of tacabrutideg compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i).

Trial Details

NCT ID
NCT06846671
Phase
PHASE3
Sponsor
BeOne Medicines
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Tacabrutideg
  • Bendamustine
  • Idelalisib
  • Rituximab
  • Venetoclax
Locations (sample)
  • Jonesboro, Arkansas, United States|35.8423,-90.70428
  • Los Angeles, California, United States|34.05223,-118.24368
  • Aurora, Colorado, United States|39.72943,-104.83192
  • Fort Myers, Florida, United States|26.62168,-81.84059
  • Atlanta, Georgia, United States|33.749,-84.38798

Key Eligibility Criteria

  • Confirmed diagnosis of CLL or SLL, requiring treatment, based on 2018 international workshop on chronic lymphocytic leukemia (iwCLL) criteria.
  • Previously received treatment for CLL/SLL with both a BTKi and a BCL2i.
  • Participants with SLL must have measurable disease by computer tomography (CT)/magnetic resonance imaging (MRI)
  • Eastern Cooperative Oncology Group (ECOG) score 0, 1, or 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →